Dernière mise à jour : 18 septembre 2012
Détails
FichiersGeneric Name:
Everolimus
État du projet:
Terminé
Domaine thérapeutique:
Pancreatic Neuroendocrine Tumour
Fabricant:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0007-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
2.5 mg, 5 mg and 10 mg
Tumour Type:
Gastrointestinal
Indications:
Pancreatic neuroendocrine tumours
Funding Request:
Patients with well- or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET) in patients with unresectable, locally advanced or metastatic disease.
Review Status:
Complete
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 18 septembre 2012